Mode
Text Size
Log in / Sign up

Fanconi Anemia

Part of Anemia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Fanconi Anemia

10 trials tracked for Fanconi Anemia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 110 citations.

10Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 7 Other / NA 2
  1. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 110 cited
  2. Phase 2 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders Completed
  3. Phase 2 Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Completed
  4. Phase 2 Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia Completed
  5. Phase 2 Pilot Study of Metformin for Patients With Fanconi Anemia Completed
  6. Phase 2 Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia Completed
Show 4 more trials
  1. Phase 2 Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 Completed
  2. Phase 2 Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia Completed
  3. N/A Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine Completed
  4. N/A Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Fanconi Anemia: what the trials found

Established clinical evidence includes the use of Cyclophosphamide, which was evaluated in multiple trials for its effects on transplant outcomes [2, 8, 9]. Specifically, data from one study showed that 71 patients experienced Grade ≥3 regimen-related toxicity, while another cohort reported a mean IgG level of 550.6 as a measure of immune reconstitution at 100 days post-transplant 2.

Anti-thymocyte globulin is established as an intervention across several trials [4, 5, 7].

Recent results — preliminary, needs further review

  • Quercetin (dietary supplement) was evaluated in a recent phase 2 trial 1.

For the clinician treating this condition

  • Cyclophosphamide has been utilized in clinical settings with documented outcomes regarding toxicity and immune reconstitution [2, 8, 9].
  • Anti-thymocyte globulin is an established intervention in the current literature [4, 5, 7].

AI synthesis of 2 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Anemia

Related studies from across the Anemia family.

Endoscopic investigation for iron deficiency anemia reveals 52.0% prevalence of normal upper gastrointestinal findings
Gastroenterology Meta-analysis
Endoscopic investigation for iron deficiency anemia reveals 52.0% prevalence of normal upper gastrointestinal findings Understanding the Common Findings in Endoscopy for Patients with Iron Deficiency
This meta-analysis of 9,807 adults with confirmed iron deficiency anemia (IDA) evaluated the prevalence of gastrointestinal findings during …
Doctors use endoscopy to find the cause of low iron. This study shows what common issues are found during these tests.
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease
Drug Pipeline Meta-analysis
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease Roxadustat Linked to Higher Risk of Blood Clots in Kidney Patients
This systematic review and meta-analysis of 11,418 adults with chronic kidney disease found that roxadustat is associated with higher odds o…
A review of over 11,000 patients suggests roxadustat may increase the risk of blood clots and death for those with chronic kidney disease.
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence
Nutrition & Obesity Medicine Meta-analysis
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence Dancers take many supplements, but benefits are often unproven and risks remain unclear
This systematic review of dietary supplement and medication use in 654 female and 86 male professional and pre-professional dancers found vi…
Dancers use many supplements and painkillers, yet benefits are limited and potential health risks need more study before we can trust them.
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients
Nephrology Meta-analysis
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients Roxadustat Boosts Hemoglobin in Peritoneal Dialysis Patients
This systematic review and meta-analysis of 607 patients receiving peritoneal dialysis found that roxadustat significantly increased hemoglo…
A review of 607 patients on peritoneal dialysis finds roxadustat raises hemoglobin and iron levels while lowering hepcidin.
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia
Pediatrics Meta-analysis
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia Liposomal iron improves blood counts and reduces side effects in children with anemia
This systematic review and meta-analysis evaluated liposomal iron versus conventional oral iron in 454 children with iron deficiency anemia …
A meta-analysis found liposomal iron raised hemoglobin more and caused fewer side effects than conventional iron in children.
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints
Neurology Sys. Review
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints Early blood boosters may lower severe brain injury risk in premature babies
A systematic review of 37 trials involving 6,724 preterm or low-birthweight infants found that early erythropoiesis-stimulating agents likel…
A review of 37 studies suggests early blood boosters might lower severe brain injury and severe gut illness in premature infants without rai…
Systematic review and meta-analysis of erythropoiesis-stimulating agents in chronic heart failure and anaemia
Cardiology Meta-analysis
Systematic review and meta-analysis of erythropoiesis-stimulating agents in chronic heart failure and anaemia New drugs help heart failure patients stay out of the hospital
This systematic review and meta-analysis evaluated erythropoiesis-stimulating agents (ESAs) in adults with chronic heart failure and anaemia…
A new review shows specific drugs can keep heart failure patients out of the hospital while improving their daily energy and movement.
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months
Drug Pipeline RCT
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months Adding Eltrombopag helps severe anemia patients recover blood counts significantly faster
This Phase 3 randomized trial reviewed patient samples from 170 untreated patients with severe or very severe aplastic anemia receiving eltr…
Adding Eltrombopag helps severe anemia patients recover blood counts faster without increasing cancer risks but genetic changes rise over ti…
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns
Pediatrics Phase II
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns Treatment for severe anemia reveals two paths to cancer risk
This phase 2 observational study followed 204 patients with severe aplastic anemia treated with immunosuppression plus eltrombopag for a med…
New research tracks cancer risks in severe anemia patients treated with standard therapy over five years
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children
Nutrition & Obesity Medicine RCT
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children Iron powders reduce malaria-related anaemia in young children
This cluster-randomized trial in 1,806 Ghanaian children aged 6-35 months found that daily iron-containing micronutrient powders for five mo…
Daily iron-based micronutrient powders can lower the risk of malaria-induced anaemia in preschool children in Ghana.
Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemia
Allergy & Immunology Cohort
Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemia A simple blood test may flag a deadly transplant complication before it starts
This prospective nested case–control study evaluated patients with severe aplastic anemia undergoing allogeneic hematopoietic stem cell tran…
A blood marker measured before transplant may flag a deadly complication in severe aplastic anemia patients.
Systematic review and meta-analysis shows dapagliflozin increases hemoglobin in chronic kidney disease patients
Nephrology Meta-analysis
Systematic review and meta-analysis shows dapagliflozin increases hemoglobin in chronic kidney disease patients Common Diabetes Drug May Help Anemia in Kidney Disease
This systematic review and meta-analysis evaluated dapagliflozin in chronic kidney disease (CKD) patients with anemia.
This study suggests a common diabetes drug could treat anemia in kidney patients without the risks of current options.